한글목차

세계 뮤코다당증 치료 시장의 미래는 병원 및 전문 클리닉 시장에서의 기회로 인해 유망합니다. 세계 뮤코다당증 치료 시장은 2025년부터 2031년까지 8.4%의 CAGR로 2031년까지 약 46억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 효과적인 치료에 대한 수요 증가, 뮤코다당증 유병률 증가, 의료비 지출 증가 등입니다.

• Lucintel의 예측에 따르면, 치료법별로는 효소보충요법이 MPS 환자의 증상과 삶의 질을 개선하고 수명을 연장할 수 있기 때문에 병원과 클리닉의 수요가 높아 앞으로도 큰 비중을 차지할 것으로 예상했습니다.
• 최종 용도별로는 병원이 MPS 치료를 제공하는 데 필요한 전문 검사실 및 장비와 같은 인프라와 숙련된 의료 전문가와 같은 전문 지식을 보유하고 있기 때문에 예측 기간 동안 가장 큰 부문을 유지할 것으로 예상됩니다.
• 지역별로 보면 북미가 높은 MPS 유병률과 잘 확립된 의료 제도 및 MPS 상환 정책으로 인해 가장 큰 시장으로 남을 것으로 보입니다.

뮤코다당증 치료 시장의 전략적 성장 기회

뮤코다당증 치료 시장은 기존 치료법의 새로운 적용을 모색하고 새로운 치료 접근법을 개발함으로써 많은 성장 잠재력을 가지고 있습니다. 뮤코다당증에 대한 인식이 높아짐에 따라 유전자 치료, 효소 대체 요법, 맞춤 치료 등 다양한 응용 분야에서 주요 성장 기회를 발굴하고, 다양한 MPS 아형에 대한 특정 니즈에 대한 타겟팅을 강화할 수 있게 되었습니다.

• 유전자 치료용 용도 확대 : 기존 효소보충요법에서 벗어나 유전자 치료용 용도의 확대는 MPS 시장에 큰 성장 기회를 가져다주고 있습니다. 현재 진행 중인 연구와 임상시험을 통해 유전자 치료는 MPS 치료의 장기적인 해결책으로 유망한 것으로 평가받고 있습니다. 이 혁신적인 접근법은 질환의 근본적인 유전적 결함을 교정하고 환자의 결과를 개선하는 동시에 평생에 걸친 개입의 필요성을 없앨 수 있는 잠재력을 가지고 있습니다. 이러한 성장 기회는 다양한 MPS 아형을 타깃으로 하는 새로운 유전자 치료제의 개발로 이어질 수 있는 막대한 투자 유치로 이어질 것으로 기대됩니다.
• 새로운 효소보충요법 개발 : MPS 치료 시장은 주요 성장 분야로서 보다 효율적이고 부작용이 적은 새로운 ERT의 개발로 이익을 얻을 수 있습니다. 기업들은 이 질환에 잘 걸리는 뇌와 같은 특정 조직이나 장기에 더 특이적으로 작용하는 차세대 ERT 개발에 관심을 기울이고 있으며, 이러한 ERT의 개발은 환자의 삶의 질을 향상시키고, 이러한 약물의 사용을 확대하며, 더 많은 사람들이 더 저렴한 가격으로 사용할 수 있도록 할 것으로 예상됩니다. 더 많은 사람들이 사용할 수 있게 될 것으로 예상됩니다.
• 신생아 선별검사 프로그램 확대 : MPS를 포함한 신생아 선별검사 프로그램의 확대는 조기 발견과 조기 개입을 가능하게 하는 또 다른 성장 기회입니다. 이러한 프로그램이 다른 국가에서도 광범위하게 시행될 경우, 조기 진단 기기 및 치료제에 대한 수요가 증가할 수 있습니다. 이러한 성장 잠재력은 조기 치료를 가능하게함으로써 환자 치료를 개선하고, 질병의 조기 진단 및 치료의 증가로 시장을 확대할 수 있습니다.
• R&D 투자 증가 : MPS 치료 관련 연구개발(R&D)에 대한 투자 증가는 중요한 성장 기회입니다. 제약회사와 연구기관들이 새로운 치료법을 개발하거나 기존 치료법을 개선하는 데 더 많은 노력을 기울인다면, 이 분야에서 혁신적인 치료법이 속속 등장할 것으로 보입니다. 이러한 투자를 통해 새로운 치료 전략이 발견되고, 환자들이 이용할 수 있는 치료 옵션이 늘어나면서 시장 성장으로 이어질 것으로 예상됩니다.

유전자 치료의 발전, 맞춤형 의료, 광범위한 스크리닝 프로그램, R&D 투자 증가, 공동 연구 등은 뮤코다당증 치료 시장의 전략적 성장 기회에 영향을 미치는 주요 요인입니다. 이러한 선택은 사용 가능한 치료법의 종류를 늘리고 시장의 상당한 확장을 촉진하고 있습니다. 이러한 전망은 희귀질환 치료 전망에서 중요한 중점 분야 중 하나로 환자들에게 새로운 삶을 가져다주고 뮤코다당증 치료 시장의 성장으로 이어질 것으로 예상됩니다.

뮤코다당증 치료 시장 활성화 요인 및 과제

뮤코다당증 치료 시장은 성장과 개척에 영향을 미치는 몇 가지 시장 촉진요인 및 과제에 의해 형성되고 있습니다. 주요 촉진요인으로는 의료기술의 발전, 희귀질환에 대한 인식 개선, 의료 인프라 확대 등을 들 수 있습니다. 반면, 심각한 장애요인으로는 고가의 치료비, 개발도상국에서의 치료 접근성 제한, 희귀질환 및 유전적으로 불균일한 질환의 치료에 따른 복잡성 등을 들 수 있습니다.

뮤코다당증 치료 시장을 이끄는 요인은 다음과 같습니다:

• 의료기술의 발전 : 유전자 치료, 차세대 효소보충요법 등 보다 효율적인 치료법 개발이 가능해졌습니다. 이러한 기술 혁신은 환자의 예후를 개선하고 치료 선택의 폭을 넓혀 새로운 치료법의 등장과 함께 시장 성장으로 이어집니다.
• 희귀질환에 대한 인식 증가 : MPS를 포함한 희귀질환에 대한 인식이 높아짐에 따라 진단 및 치료법에 대한 수요가 증가하고 있습니다. 옹호 활동과 교육 프로그램이 조기 발견과 치료법 개선으로 이어지면서 환자 기반이 확대되고 이에 따라 시장 규모가 확대되고 있습니다.
• 의료 인프라의 확대 : 특히 개발도상국의 의료 및 인프라 개발로 인해 더 많은 사람들이 MPS 치료에 접근할 수 있게 되었습니다. 의료 수준 향상으로 더 많은 환자들이 MPS 전문 치료를 받을 수 있게 됨에 따라 치료 솔루션과 검사 도구에 대한 수요는 지속적으로 증가할 것으로 보입니다.

뮤코다당증 치료 시장의 과제는 다음과 같습니다:

• 높은 치료비 : 유전자 치료와 효소보충요법을 포함한 MPS 치료는 고가이며, 환자와 의료시스템에 큰 도전이 될 수 있습니다. 특히 신흥국에서는 비용 문제로 인해 이러한 치료법에 대한 접근이 제한될 수 있으며, 이는 시장 개척의 장벽으로 작용할 수 있습니다.
• 개발도상국에서의 치료 접근성 제한 : 부족한 의료 인프라, 높은 비용, 낮은 인지도로 인해 개발도상국에서는 MPS 치료에 대한 접근성이 제한되어 있습니다. 이 문제는 시장 확대에 걸림돌이 되고 있으며, 의료 혜택이 충분하지 않은 지역 전체에서 중요한 약품에 대한 접근성을 향상시킬 수 있는 방법이 필요함을 강조합니다.
• 희귀하고 다양한 질환의 치료의 복잡성 : MPS는 유전적으로 다양한 질환군으로 구성되어 있어 효과적인 치료법 개발 및 제공에 어려움을 겪고 있습니다. 다양한 병태생리로 인해 전문적인 치료가 필요하고, 대규모 수요에 대한 대응이 어려워 시장 확대에 걸림돌이 되고 있습니다.

뮤코다당증 치료 시장은 기술 발전, 지식의 증가, 탄탄한 의료 시스템, R&D 비용 증가, 지원적 규제에 힘입어 성장하고 있습니다. 그러나 치료비 상승, 저개발국에서의 접근성 제한, 희귀하고 이질적인 질환인 뮤코다당증 관리의 복잡성 등 여러 도전과제에 직면해 있습니다. 이러한 시장 촉진요인과 과제는 시장 궤적을 형성하고, 전 세계 환자들에게 접근성과 유효성을 보장하기 위해 필요한 새로운 치료법과 전략 개발에 영향을 미치고 있습니다.

목차

제1장 주요 요약

제2장 세계의 뮤코다당증 치료 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 뮤코다당증 치료 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 뮤코다당증 치료 시장 : 종류별
  • MPS-I
  • MPS-II
  • MPS-IV
  • MPS-VI
  • MPS-VII
  • 기타
• 세계의 뮤코다당증 치료 시장 : 치료법별
  • 효소보충요법
  • 줄기세포 치료
• 세계의 뮤코다당증 치료 시장 : 최종 용도별
  • 병원
  • 전문 클리닉
  • 기타

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 세계의 뮤코다당증 치료 시장 : 지역별
• 북미의 뮤코다당증 치료 시장
• 유럽의 뮤코다당증 치료 시장
• 아시아태평양의 뮤코다당증 치료 시장
• 기타 지역의 뮤코다당증 치료 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 뮤코다당증 치료 시장 성장 기회 : 종류별
  • 세계의 뮤코다당증 치료 시장 성장 기회 : 치료법별
  • 세계의 뮤코다당증 치료 시장 성장 기회 : 최종 용도별
  • 세계의 뮤코다당증 치료 시장 성장 기회 : 지역별
• 세계의 뮤코다당증 치료 시장 최신 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 뮤코다당증 치료 시장 생산능력 확대
  • 세계의 뮤코다당증 치료 시장 기업 인수합병(M&A), 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• Take da Pharmaceutical
• BioMarin Pharmaceuticals
• Ultragenyx Pharmaceutical
• Sarepta Therapeutics
• Abeona Therapeutics
• Eloxx Pharmaceuticals
• Esteve
• Immusoft Corporation
• Inventiva
• GC Pharma

영문목차

The future of the global mucopolysaccharidosis treatment market looks promising with opportunities in the hospital and specialty clinic markets. The global mucopolysaccharidosis treatment market is expected to reach an estimated $4.6 billion by 2031 with a CAGR of 8.4% from 2025 to 2031. The major drivers for this market are the increasing demand for effective treatments, the rising prevalence of mucopolysaccharidosis, and rising healthcare spending.

• Lucintel forecasts that, within the treatment category, enzyme replacement therapy will remain the larger segment due to high demand from hospitals and clinics as it helps to improve the symptoms and quality of life for MPS patients, and it can also extend their lifespan.
• Within the end use category, hospitals will remain the largest segment over the forecast period because it has the necessary infrastructure, such as specialized laboratories and equipment, and the necessary expertise like trained healthcare professionals, to provide MPS treatment.
• In terms of regions, North America will remain the largest segment due to the high prevalence of MPS supported by a well-established healthcare system and MPS reimbursement policy.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Mucopolysaccharidosis Treatment Market

The mucopolysaccharidosis treatment market is undergoing significant changes driven by emerging trends that define the future of care for patients with these rare genetic disorders. These trends have been influenced by progress in biotechnology, rising global awareness, and a changing regulatory environment. Understanding these trends is crucial for stakeholders in the MPS treatment market as they shed light on areas of research focus and development, which may result in improved or new drugs that can better suit patients' needs.

• Increase in Gene Therapy Research: Gene therapy is emerging as a potential trend in the MPS treatment industry, with the possibility of addressing diseases at their root for long-term solutions. This area of research has witnessed remarkable growth, currently involving several clinical trials aimed at determining the suitability and safety of gene therapies for different types of MPS. These interventions help correct defects traced back to changes in genes by introducing functional ones, potentially offering a single treatment route with a high chance of better patient outcomes. The results obtained from these tests could be miraculous, serving as signs of hope for finding a cure for MPS.
• Progress in Enzyme Replacement Therapies (ERTs): Enzyme replacement therapies (ERTs) have remained the pillar of MPS treatment, augmented through continuous improvement initiatives. Patient experience can be enhanced through new formulations and methods of drug administration, leading to reduced administration rates and increased efficacy for ERTs. Due to these improvements, it is becoming easier to use enzyme replacement treatments not only in hospital settings but also at home, making ERTs particularly important for the long-term care of patients suffering from MPS.
• Expanding Newborn Screening Programs for MPS: The expansion of newborn screening programs for MPS is a crucial trend that enhances early diagnosis and intervention. Early detection allows for the timely initiation of treatment, which can greatly improve the prognosis for patients with MPS. Supported by developments in diagnostic technologies, these screening programs are increasingly becoming prevalent worldwide. This wave is expected to lead to better patient outcomes and reduced disease burden, as early interventions can prevent or mitigate many severe complications related to MPS.
• Increasing Global Awareness and Advocacy: There is a growing global awareness and advocacy for MPS through patient organizations, healthcare professionals, and social media, boosting their visibility. These efforts help the public understand more about MPS while informing policymakers on how to improve access to treatments and support research funding. Through advocacy initiatives, comprehensive care models have been developed to improve the quality of life for individuals living with MPS. As this awareness continues to grow, it is projected to drive further progress in the management and treatment of MPS.

The unfolding trends in the MPS treatment market, ranging from gene therapy research to personalized medicine, are changing how patients with these rare genetic disorders are cared for. These changes will continue evolving into greater improvements in treatment options, making therapies better, more accessible, and individually focused to meet patients' needs. There are prospects for better treatments for MPS due to ongoing research and innovation that could lead to discoveries along incredible paths.

Recent Developments in the Mucopolysaccharidosis Treatment Market

The mucopolysaccharidosis treatment market is experiencing significant advancements as new therapies and approaches are developed to manage and treat this group of rare, inherited metabolic disorders. With increased investment in research, advancements in gene therapy, and greater awareness among healthcare professionals, the landscape for mucopolysaccharidosis (MPS) treatment is rapidly evolving. These developments are not only expanding the treatment options available to patients but are also paving the way for more personalized and effective therapies.

• Advancements in Gene Therapy: Gene therapy is emerging as a promising treatment for MPS, offering the potential to address the underlying genetic defects responsible for the disorder. Recent clinical trials have shown positive results, with some therapies moving into advanced stages of development. These advancements are significant as they provide a potential one-time treatment option that could greatly improve patient outcomes. The impact of gene therapy on the MPS market is expected to be transformative, potentially reducing the need for lifelong enzyme replacement therapies and other ongoing treatments.
• Improved Enzyme Replacement Therapies (ERT): The replacement of enzymes via infusion is the most significant treatment approach for MPS patients, but this is now being improved to enhance the efficacy and versatility of enzyme replacement therapies. New formulations are being developed that will improve bioavailability as well as reduce the frequency of administration. Moreover, research is being conducted to address certain limitations related to ERT, such as its inability to cross the blood-brain barrier. These changes in ERT predict significant improvements in compliance and outcomes, thus cementing its place as a management strategy for MPS.
• Increased Attention on Early Diagnosis and Screening: Significant improvements have been made in relation to early diagnosis and screening for MPS, including an increase in the global adoption of newborn screening programs by many countries. Advanced diagnostic methods now allow for early detection before any permanent damage occurs. These developments are life-changing, as earlier diagnosis could lead to better disease control, increased quality of life among patients, and reduced healthcare costs over time.
• The Rise of Customized Medication: Personalized medicine, which is increasingly crucial in the treatment of MPS, customizes therapy to fit specific genetic mutations in patients. This enables a more targeted and effective therapeutic approach, reducing side effects and improving patient outcomes. This shift may revolutionize the MPS market regarding personalized treatment protocols, leading to hopes of better disease management and improved long-term results for patients.

The mucopolysaccharidosis treatment market is evolving quickly due to recent developments that will allow for more efficient treatments. Advances in gene therapy, improvements in enzyme replacement therapies, early detection methods, personalized medicine, and collaborative research are rapidly changing the landscape. These developments not only improve the lives of patients but also provide new market opportunities for pharmaceutical companies. Over time, the MPS treatment market may grow significantly and change dramatically as innovative treatments reach more people.

Strategic Growth Opportunities for Mucopolysaccharidosis Treatment Market

The mucopolysaccharidosis treatment market has many growth prospects due to the exploration of new applications of existing therapies and the development of novel treatment approaches. Awareness about the disease enhances targeting of specific needs in different MPS subtypes, boosting the identification of key growth opportunities across diverse applications such as gene therapy, enzyme replacement therapy, or personalized medicine, among others.

• Gene Therapy Application Expansion: The expansion of gene therapy applications beyond traditional enzyme replacement therapies presents a major growth opportunity in the MPS market. Ongoing research and clinical trials make gene therapy promising as a long-term solution for treating MPS. This transformative approach has the potential to correct genetic defects underlying the ailment, obviating the need for lifelong interventions while improving outcomes for patients. This growth opportunity is expected to attract significant investment and lead to the development of new gene therapies targeting diverse MPS subtypes.
• New Enzyme Replacement Therapies Development: The MPS treatment market can benefit from the creation of novel ERTs that are more efficient and have fewer side effects as a key growth area. Companies are interested in developing next-generation ERTs that can be more specific for certain tissues or organs, such as the brain, which is commonly affected by this illness. These developments in ERT are anticipated to enhance patients' quality of life and expand the use of these drugs, making them more affordable for a wider range of people.
• Expansion of Newborn Screening Programs: Expanded newborn screening programs to include MPS represent another opportunity for growth, enabling early identification and intervention. Wider implementation of these programs by other countries may result in higher demand for diagnostic devices and therapies at early stages. This growth possibility improves patient care by allowing for early treatment and extends the market, as there would be more diagnoses and treatments made at earlier stages of the disease.
• Increasing Investment in Research and Development: Increased investment in research and development (R&D) for MPS treatments is a vital growth opportunity. When pharmaceutical firms and research institutions focus more on developing new therapies and improving existing ones, this sector will experience an influx of innovative treatments. This investment is anticipated to result in the identification of fresh therapeutic strategies, increasing the treatment options available for patients, which, in turn, will lead to market growth.

Gene therapy advances, individualized medicine, wider screening programs, increased investments in R&D, and collaboration are the main factors influencing strategic growth opportunities in the mucopolysaccharidosis treatment market. These options are broadening the variety of remedies available and driving significant market expansion. The ongoing realization of these prospects is expected to lead to growth in the MPS treatment market, bringing new life to patients as one of the key focus areas within the landscape for rare disease treatment.

Mucopolysaccharidosis Treatment Market Driver and Challenges

The mucopolysaccharidosis treatment market is shaped by several drivers and challenges that affect its growth and development. Key influencers include advances in medical technology, greater awareness of rare diseases, and an expanding healthcare infrastructure. On the other hand, significant hurdles include high treatment costs, limited access to therapies in developing countries, and the complexities involved in treating rare and genetically heterogeneous diseases.

The factors driving the mucopolysaccharidosis treatment market include:

• Technological Advancements in Medical Technology: Technological advancements are the primary driving factor for the MPS treatment market, enabling the development of more efficient therapies such as gene therapy and next-generation enzyme replacement therapies. These innovations improve patient outcomes and expand the range of therapeutic options, leading to market growth as new treatments become available.
• Heightened Awareness of Rare Diseases: Increasing awareness of rare diseases, including MPS, is contributing to a rise in demand for diagnostic methods and therapies. Advocacy efforts and educational programs have led to earlier detection and improved care, thereby expanding the patient base and boosting market size accordingly.
• Expanding Healthcare Infrastructure: The growth of healthcare infrastructure, especially in developing areas, has made it possible for more people to access MPS treatments. Demand for therapeutic solutions and testing tools will continue to rise as more patients can access specialized MPS medical attention due to improving healthcare standards.

Challenges in the mucopolysaccharidosis treatment market include:

• High Cost of Treatment: MPS treatment, including gene therapy and enzyme replacement therapy, is expensive, posing a significant challenge for patients and healthcare systems. Consequently, access to these therapies may be limited due to cost implications, especially in developing countries, creating barriers to market growth.
• Limited Access to Therapies in Developing Regions: Inadequate healthcare infrastructure, high costs, and low awareness levels contribute to limited access to MPS treatments in developing regions. This problem hampers market expansion and highlights the need for methods to enhance accessibility to these critical drugs across underserved areas.
• Complexities of Treating a Rare and Diverse Disease: MPS comprises a genetically diverse group of diseases that present challenges in developing and delivering effective therapies. The varied presentations require specialized treatments, making it difficult to address needs on a large scale, hindering market expansion.

The mucopolysaccharidosis treatment market has been driven by technological advancements, increased knowledge, robust healthcare systems, rising expenditures in research and development, and supportive regulations. However, it also faces challenges such as high treatment costs, limited accessibility in underdeveloped countries, and the complexities of managing a rare and heterogeneous disorder. These drivers and challenges are shaping the market's trajectory, influencing the development of new therapies and strategies needed to ensure their accessibility and effectiveness for patients worldwide.

List of Mucopolysaccharidosis Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies mucopolysaccharidosis treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the mucopolysaccharidosis treatment companies profiled in this report include-

• Take da Pharmaceutical
• BioMarin Pharmaceuticals
• Ultragenyx Pharmaceutical
• Sarepta Therapeutics
• Abeona Therapeutics
• Eloxx Pharmaceuticals
• Esteve
• Immusoft Corporation
• Inventiva
• GC Pharma

Mucopolysaccharidosis Treatment by Segment

The study includes a forecast for the global mucopolysaccharidosis treatment market by type, treatment, end use, and region.

Mucopolysaccharidosis Treatment Market by Type [Analysis by Value from 2019 to 2031]:

• MPS-I
• MPS-II
• MPS-IV
• MPS-VI
• MPS-VII
• Others

Mucopolysaccharidosis Treatment Market by Treatment [Analysis by Value from 2019 to 2031]:

• Enzyme Replacement Therapy
• Stem Cell Therapy

Mucopolysaccharidosis Treatment Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Specialty Clinics
• Others

Mucopolysaccharidosis Treatment Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Mucopolysaccharidosis Treatment Market

The mucopolysaccharidosis (MPS) treatment market has seen significant advancements in recent years, driven by growing research efforts and increased awareness of these rare genetic disorders. MPS disorders are characterized by the body's inability to break down certain complex carbohydrates, necessitating targeted treatments that are evolving with new therapies and improved diagnostics. This is a global market, with key developments being reported in major regions such as China, Germany, Japan, India, and the United States.

• United States: The United States has made great strides in the treatment of MPS, evidenced by ongoing clinical trials and FDA approvals for novel enzyme replacement therapies (ERTs) and gene therapy. Additionally, there has been an increasing trend toward collaboration between pharmaceutical companies and research institutes to develop groundbreaking treatments. Recent developments include the scaling up of newborn screening programs aimed at the early detection of MPS, enabling timely intervention. Consequently, these activities are helping patients recover faster while promoting the development of personalized therapeutic options tailored to different types of MPS.
• China: MPS is gaining more attention in China as the government invests in research and development to serve patients with such conditions. Programs offering specialized healthcare have been initiated to enhance the diagnosis and management of MPS while increasing the availability of ERTs. Moreover, Chinese biopharmaceutical companies are beginning to explore gene therapy options aimed at delivering improved and long-lasting therapies. These developments have gradually enhanced access to care for MPS patients in China.
• Germany: Germany leads in rare disease research, particularly concerning MPS cases. The country is spearheading advanced therapy development centered on ERT and gene therapy. Additionally, specialized treatment centers for MPS are being established, providing comprehensive care from diagnosis through long-term management. German researchers are also participating in international collaborations to find novel therapeutic avenues and enhance the quality of life for MPS patients. As such, Germany has emerged as a major contributor to the global MPS treatment industry.
• India: Diagnosis of MPS in India has improved significantly, though challenges with treatment access remain. Numerous initiatives by healthcare providers aim to enhance diagnostic services and ERT options in the country. Indian pharmaceutical firms, collaborating with global companies, are facilitating the availability of new therapeutic options in the market. However, accessibility remains a significant issue, especially regarding making treatments more affordable for all potentially affected individuals. Nonetheless, India is progressing in the welfare of MPS patients.
• Japan: Japan has recorded significant milestones in MPS treatment recently, focusing on rare diseases and orphan drugs. Supportive regulatory frameworks facilitating the development and approval of MPS treatment options have been implemented in the country. Japan is also exploring revolutionary treatment strategies such as gene therapy and regenerative medicine, which could be effective for individuals living with MPS. Developments like these include introducing new ERTs and expanding clinical trials for emerging therapies. These activities have improved care standards for Japanese patients with MPS and contributed to global research initiatives.

Features of the Global Mucopolysaccharidosis Treatment Market

Market Size Estimates: Mucopolysaccharidosis treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Mucopolysaccharidosis treatment market size by type, treatment, end use, and region in terms of value ($B).

Regional Analysis: Mucopolysaccharidosis treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, treatments, end uses, and regions for the mucopolysaccharidosis treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the mucopolysaccharidosis treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the mucopolysaccharidosis treatment market by type (MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, and others), treatment (enzyme replacement therapy and stem cell therapy), end use (hospitals, specialty clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Mucopolysaccharidosis Treatment Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Mucopolysaccharidosis Treatment Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Mucopolysaccharidosis Treatment Market by Type
  • 3.3.1: MPS-I
  • 3.3.2: MPS-II
  • 3.3.3: MPS-IV
  • 3.3.4: MPS-VI
  • 3.3.5: MPS-VII
  • 3.3.6: Others
• 3.4: Global Mucopolysaccharidosis Treatment Market by Treatment
  • 3.4.1: Enzyme Replacement Therapy
  • 3.4.2: Stem Cell Therapy
• 3.5: Global Mucopolysaccharidosis Treatment Market by End Use
  • 3.5.1: Hospitals
  • 3.5.2: Specialty Clinics
  • 3.5.3: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Mucopolysaccharidosis Treatment Market by Region
• 4.2: North American Mucopolysaccharidosis Treatment Market
  • 4.2.1: North American Mucopolysaccharidosis Treatment Market by Treatment: Enzyme Replacement Therapy and Stem Cell Therapy
  • 4.2.2: North American Mucopolysaccharidosis Treatment Market by End Use: Hospitals, Specialty Clinics, and Others
• 4.3: European Mucopolysaccharidosis Treatment Market
  • 4.3.1: European Mucopolysaccharidosis Treatment Market by Treatment: Enzyme Replacement Therapy and Stem Cell Therapy
  • 4.3.2: European Mucopolysaccharidosis Treatment Market by End Use: Hospitals, Specialty Clinics, and Others
• 4.4: APAC Mucopolysaccharidosis Treatment Market
  • 4.4.1: APAC Mucopolysaccharidosis Treatment Market by Treatment: Enzyme Replacement Therapy and Stem Cell Therapy
  • 4.4.2: APAC Mucopolysaccharidosis Treatment Market by End Use: Hospitals, Specialty Clinics, and Others
• 4.5: ROW Mucopolysaccharidosis Treatment Market
  • 4.5.1: ROW Mucopolysaccharidosis Treatment Market by Treatment: Enzyme Replacement Therapy and Stem Cell Therapy
  • 4.5.2: ROW Mucopolysaccharidosis Treatment Market by End Use: Hospitals, Specialty Clinics, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Mucopolysaccharidosis Treatment Market by Type
  • 6.1.2: Growth Opportunities for the Global Mucopolysaccharidosis Treatment Market by Treatment
  • 6.1.3: Growth Opportunities for the Global Mucopolysaccharidosis Treatment Market by End Use
  • 6.1.4: Growth Opportunities for the Global Mucopolysaccharidosis Treatment Market by Region
• 6.2: Emerging Trends in the Global Mucopolysaccharidosis Treatment Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Mucopolysaccharidosis Treatment Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Mucopolysaccharidosis Treatment Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Take da Pharmaceutical
• 7.2: BioMarin Pharmaceuticals
• 7.3: Ultragenyx Pharmaceutical
• 7.4: Sarepta Therapeutics
• 7.5: Abeona Therapeutics
• 7.6: Eloxx Pharmaceuticals
• 7.7: Esteve
• 7.8: Immusoft Corporation
• 7.9: Inventiva
• 7.10: GC Pharma